<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Korean J Hepatol</journal-id>
      <journal-id journal-id-type="publisher-id">KJHEP</journal-id>
      <journal-title-group>
        <journal-title>The Korean Journal of Hepatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1738-222X</issn>
      <issn pub-type="epub">2093-8047</issn>
      <publisher>
        <publisher-name>The Korean Association for the Study of the Liver</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21494079</article-id>
      <article-id pub-id-type="pmc">3304626</article-id>
      <article-id pub-id-type="doi">10.3350/kjhep.2011.17.1.61</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Vogt-Koyanagi-Harada disease occurring during pegylated interferon-&#x3B1;2b and ribavirin combination therapy for chronic hepatitis C</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lim</surname>
            <given-names>Jae Hee</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Yun Nah</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Young Seok</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Sang Gyune</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jeong</surname>
            <given-names>Seung Won</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jang</surname>
            <given-names>Jae Young</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hong Soo</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Sae Hwan</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Tae Kwann</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Bucheon, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Ophthalmology, Soon Chun Hyang University College of Medicine, Bucheon, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Young Seok Kim. Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, 1174 Jung-dong, Wonmi-gu, Bucheon 420-767, Korea. Tel. +82-32-621-5085, Fax. +82-32-621-5018, <email>liverkys@schmc.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>3</month>
        <year>2011</year>
      </pub-date>
      <volume>17</volume>
      <issue>1</issue>
      <fpage>61</fpage>
      <lpage>65</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>23</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>9</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2011 by The Korean Association for the Study of the Liver</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-&#x3B1;2b and ribavirin combination therapy for chronic hepatitis C.</p>
      </abstract>
      <kwd-group>
        <kwd>Vogt-Koyanagi-Harada disease</kwd>
        <kwd>Interferon-&#x3B1;2b</kwd>
        <kwd>Chronic hepatitis C</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Interferon combined with ribavirin is commonly used in treating chronic hepatitis C. Interferon sometimes results in common side effects such as flu-like symptoms, fatigue, myalgia, headache, and in rare but fatal ones such as depression, suppressed bone marrow, interstitial pneumonia, diabetes, or autoimmune diseases.<xref ref-type="bibr" rid="B1">1</xref> Vogt-Koyanagi-Harada (VKH) disease is a multi-systemic granulomatous inflammatory disease with ophthalmic involvement (uveitis and retinal detachment), ear and meningeal involvement (headache, tinnitus, and encephalomeningitis), and skin and hair change (vitiligo, alopecia, and poliosis). It is a very rare complication associated with the interferon treatments.<xref ref-type="bibr" rid="B2">2</xref> The mechanism of VKH disease has not been known yet, but it is presumed that interferon brings alterations to the immunological responses to melanocytes.<xref ref-type="bibr" rid="B3">3</xref> We report a case of VKH disease which occurred during pegylated interferon and ribavirin therapy for chronic hepatitis C.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 58-year-old woman visited our hospital for evaluation of chronic hepatitis C. The patient was diagnosed as chronic hepatitis C 10 years ago, but had not received any treatment. She had been taking amlodipine 5 mg for hypertension for 8 years. She had no history of alcohol consumption, smoking, or injection drug use. Dermatological, pulmonary, cardiac and neurological examinations were normal. On her first visit to our hospital, the liver function test and the complete blood cell count were normal, and the serologic tests for hepatitis A and B and HIV were negative. She was infected with hepatitis C virus (HCV) genotype 1b, and HCV RNA level was 3.8&#xD7;10<sup>6</sup> copies/mL. There were no specific findings except for the hepatic cyst from abdominal CT scan. Liver biopsy was recommended to evaluate liver inflammation and fibrosis, but she refused. She was commenced on pegylated interferon-&#x3B1;2b 80 &#xB5;g (1.5 &#xB5;g/kg) weekly by subcutaneous injection and ribavirin 400 mg orally twice daily. Serum HCV RNA level decreased below 25 copies/mL within 12 weeks after the start of interferon, thus she achieved an early viral response.</p>
      <p>After 9 months of interferon and ribavirin treatment, the patient complained of blurred vision and headache. On physical examination, the vitiligo around her forehead and scalp was shown (<xref ref-type="fig" rid="F1">Fig. 1</xref>), but there was no sign of meningeal irritation. Optic fundal examination showed uveitis and retinal edema. Retinal fluorescein angiography (<xref ref-type="fig" rid="F2">Fig. 2</xref>) showed leakage of fluorescein dye from the choroid into the subretinal space. The serous retinal detachment was seen clearly in the right eye from optimal coherence tomography (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). Cerebrospinal fluid examination and the magnetic resonance imaging (MRI) to identify the encephalomeningitis showed no abnormal findings. The level of angiotensin-converting enzyme showed normal range, the erythrocyte sedimentation rate and the C-reactive protein were also normal, and the antinuclear antibody and the rheumatoid factor were negative. She was diagnosed as having incomplete VKH disease, therefore pegylated interferon-&#x3B1;2b and ribavirin were discontinued, and intravenous pulses of methylprednisolone at a dose of 1 g for 3 days, followed by daily oral administration at a dose of 60 mg prednisolone were introduced. After 2 weeks of steroid therapy, her eyesight was getting better, and retinal detachment disappeared (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). Prednisolone was progressively tapered to 10 mg daily during next two months, but relapse occurred. Intravenous pulses of methylprednisolone followed by oral prednisolone were performed. The uveitis and visual acuity improved. While the HCV RNA had not been detected during the treatment of pegylated interferon-&#x3B1;2b and ribavirin, serum HCV RNA level increased to 3.0&#xD7;10<sup>7</sup>copies/mL after ceasing of interferon based therapy. Oral prednisolone was slowly tapered to 10 mg daily and no relapse occurred.</p>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>Most of ophthalmological complications occurring during interferon therapy are benign, transient, and characterized by interferon-related retinopathy. Incidence of interferon-related retinopathy such as hemorrhage and cotton wool spots vary from 6 to 13%.<xref ref-type="bibr" rid="B4">4</xref> The rate of these complications is reported to be higher in patients with diabetes or hypertension, but is not related with HCV genotypes, platelet counts or types or dose of interferon.<xref ref-type="bibr" rid="B5">5</xref> More than 90% of the retinal diseases during the interferon treatment occur within the first 8 weeks. Therefore, the retinal test must be carefully implemented from the time before interferon treatment to the 8 weeks after initial treatment. Even though it can lead to permanent vision loss without proper treatment in the early stage, most retinal complications were asymptomatic, not associated with impairment of visual acuity, and reversible after discontinuation of interferon therapy.<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref> There are two severe forms of intraocular complications which result in severe visual impairment. The first form is represented by VKH, one of the inflammatory intraocular disorders and the second form is retinal vascular disorders including central retinal arterial/venous occlusion.</p>
      <p>The VKH disease was first described as poliosis, vitiligo, anterior uveitis, and tinnitus by Vogt and Koyanagi, and described as posterior uveitis with retinal detachment by Harada in 1926. The VKH disease is a rare multisystem syndrome that attacks melanocytes-containing tissue such as eye, skin, hair, inner ear, and cerebral meninges.<xref ref-type="bibr" rid="B3">3</xref> This can be divided into 4 phases; prodromal neurologic phase, acute uveitis phase, chronic convalescent phase that is characterized by a progressive depigmentation of the skin and the fundus, and chronic recurrent phase.<xref ref-type="bibr" rid="B8">8</xref> This mainly occurs in 30 to 40 year old women and more frequently in Asian, Latino, Native American, or Asian Indian.<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></p>
      <p>The pathophysiological mechanism of this disease is not obviously known, but it is presumed to be an autoimmune response of the type 1 helper T-cell (Th1) to antigens related with melanocytes.<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref> This can be supported by the fact that when lymphocytes of the patient with VKH are exposed to melanocytes, the lymphocytes proliferate significantly.<xref ref-type="bibr" rid="B11">11</xref> Cutaneous injury or viral infection may induce sensitization of melanocyte and may precipitate the VKH disease. And also, thyroid disease or rheumatoid arthritis can be associated with VKH disease.<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref></p>
      <p>Interferon enhances lymphocyte cytotoxicity, reveals class I antigens of major histocompatibility complex, and differentiates antigen-presenting cells. It might also make people sensitive to autoimmune diseases easily get ill through increasing the productions of proinflammatory cytokines, and worsen autoimmune diseases such as lupus, rheumatoid arthritis, and psoriasis.<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref> Indeed, there are a few case reports about VKH disease occurrence in the treatment combined with interferon and ribavirin for chronic hepatitis C.<xref ref-type="bibr" rid="B16">16</xref></p>
      <p>The occurrence of VKH disease in patient with HCV infection before interferon therapy also arouses suspicion regarding the role of the HCV in the pathogenesis of the disease.<xref ref-type="bibr" rid="B16">16</xref> Molecular mimicry between viral antigens and melanocyte-related antigens could lead to VKH disease. However, most reports about its occurrence during interferon treatment for chronic hepatitis C suggest that interferon therapy rather than HCV infection per se may play a role in the development of VKH.<xref ref-type="bibr" rid="B17">17</xref></p>
      <p>In order to achieve successful outcome and to prevent complications associated with interferon, selection of patients for the treatment is most important. Generally, the ones who have persistently normal alanine aminotransferase (ALT) levels were not a good candidate for the treatment since individuals with persistently normal ALT values have significantly less liver fibrosis than whom that have abnormal ALT levels.<xref ref-type="bibr" rid="B18">18</xref> In this case, her liver function tests were normal on her first visit to our hospital, but levels of transaminase had been shown above than 40 IU/L several times in her family doctor's clinic. Therefore she was not a person who had persistently normal ALT levels, and was worried about progression of liver disease and wanted to treat chronic hepatitis C. Hence, we decided to start interferon and ribavirin therapy without confirm of liver histology.</p>
      <p>The revised diagnostic criteria of VKH disease (<xref ref-type="table" rid="T1">Table 1</xref>) has been clarified.<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref> While five items must be satisfied to be diagnosed as a complete VKH disease, it is diagnosed as an incomplete VKH disease when four items including a symptom among neurologic or dermatological conditions are satisfied. The present patient had no vitiligo before the interferon therapy (<xref ref-type="fig" rid="F1">Fig. 1A</xref>), after 9 months of starting interferon therapy, about 5 cm sized patches of de-pigmentation were seen around both lateral side of her forehead symmetrically. Thus the patient met the criteria for incomplete VKH disease.</p>
      <p>The treatment of the VKH disease is performed mainly using high dose of steroid, and the aggressive treatment in the early stage is important to turn around the eye-related symptoms.<xref ref-type="bibr" rid="B9">9</xref> Administration of corticosteroid and stopping antiviral agents controlled ocular manifestations in the past reports about VKH disease associated with interferon/ribavirin. Also in our case, discontinuation of interferon/ribavirin and high-dose systemic steroid therapy could improve ocular changes and visual outcomes. To treat the recurrent or steroid-resistant VKH disease, cyclosporine, antimetabolites, and alkylating agent have been used.<xref ref-type="bibr" rid="B19">19</xref></p>
      <p>Several treatment modalities can improve vitiligo. Commonly used repigmentation therapies including ultraviolet light and/or topical applications of corticosteroids or calcineurin inhibitors are sometimes effective.<xref ref-type="bibr" rid="B20">20</xref> Depigmentation of the unaffected skin is another option in cases of extensive vitiligo. However, there is no cure for vitiligo. In this case, her skin lesions were not improved despite systemic and topical corticosteroid agents.</p>
      <p>In summary, VKH disease, which can be induced by pegylated interferon-&#x3B1;2b and ribavirin combination therapy may lead to irreversible visual loss. Thereby, awareness of screening for ocular manifestations and early treatment are necessary.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>VKH</term>
          <def>
            <p>Vogt-Koyanagi-Harada</p>
          </def>
        </def-item>
        <def-item>
          <term>HIV</term>
          <def>
            <p>human immunodeficiency virus</p>
          </def>
        </def-item>
        <def-item>
          <term>HCV</term>
          <def>
            <p>hepatitis C virus</p>
          </def>
        </def-item>
        <def-item>
          <term>RNA</term>
          <def>
            <p>ribonucleic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>ALT</term>
          <def>
            <p>alanine aminiotransferase</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fattovich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giustina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Favarato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ruol</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon</article-title>
          <source>J Hepatol</source>
          <year>1996</year>
          <volume>24</volume>
          <fpage>38</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">8834023</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasahara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hiraide</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Iwahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Imagawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ohguro</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C</article-title>
          <source>J Gastroenterol</source>
          <year>2004</year>
          <volume>39</volume>
          <fpage>1106</fpage>
          <lpage>1109</lpage>
          <pub-id pub-id-type="pmid">15580406</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vancoillie</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nayaert</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Melanocyte biology and its implications for the clinician</article-title>
          <source>Eur J Dermatol</source>
          <year>1999</year>
          <volume>9</volume>
          <fpage>241</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">10210794</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bowen</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Vyas</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Blurred vision: cause? Retinopathy secondary to interferon treatment</article-title>
          <source>Gut</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>211</fpage>
          <fpage>251</fpage>
          <pub-id pub-id-type="pmid">16407386</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shigehira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Retinal complications during interferon therapy for chronic hepatitis C</article-title>
          <source>Am J Gastroenterol</source>
          <year>1996</year>
          <volume>91</volume>
          <fpage>309</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">8607498</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perlemuter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cacoub</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sba&#xEF;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hausfater</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thibault</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>TH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatitis C virus infection in systemic lupus erythematosus: a case-control study</article-title>
          <source>J Rheumatol</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>1473</fpage>
          <lpage>1478</lpage>
          <pub-id pub-id-type="pmid">12858443</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zegans</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Anninger</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Ocular manifestations of hepatitis C virus infection</article-title>
          <source>Curr Opin Ophthalmol</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>423</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">12441848</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moorthy</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Inomata</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada syndrome</article-title>
          <source>Surv Ophthalmol</source>
          <year>1995</year>
          <volume>39</volume>
          <fpage>265</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="pmid">7725227</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada disease</article-title>
          <source>Curr Opin Ophthalmol</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>437</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">11141638</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brassard</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Grace</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bordens</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Interferon-alpha as an immunotherapeutic protein</article-title>
          <source>J Leukoc Biol</source>
          <year>2002</year>
          <volume>71</volume>
          <fpage>565</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="pmid">11927642</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hammer</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Cellular hypersensitivity to uveal pigment confirmed by leucocyte migration tests in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome</article-title>
          <source>Br J Ophthalmol</source>
          <year>1974</year>
          <volume>58</volume>
          <fpage>773</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="pmid">4473998</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiesli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bernauer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Furrer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Headache and bilateral visual loss in a young hypothyroid Indian man</article-title>
          <source>J Endocrinol Invest</source>
          <year>1999</year>
          <volume>22</volume>
          <fpage>141</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">10195382</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shinzato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Yoshinari</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Bonf&#xE1;</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Eye disease in a patient with rheumatoid arthritis</article-title>
          <source>Postgrad Med J</source>
          <year>1999</year>
          <volume>75</volume>
          <fpage>676</fpage>
          <lpage>677</lpage>
          <pub-id pub-id-type="pmid">10621881</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Downs</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Dunnill</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2000</year>
          <volume>25</volume>
          <fpage>351</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="pmid">10971502</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Passos de Souza</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Evangelista Segundo</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Jos&#xE9;</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Lemaire</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Santiago</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Rheumatoid arthritis induced by alpha-interferon therapy</article-title>
          <source>Clin Rheumatol</source>
          <year>2001</year>
          <volume>20</volume>
          <fpage>297</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">11529644</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Touitou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bodaghi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cassoux</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Cacoub</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C</article-title>
          <source>Am J Ophthalmol</source>
          <year>2005</year>
          <volume>140</volume>
          <fpage>949</fpage>
          <lpage>952</lpage>
          <pub-id pub-id-type="pmid">16310490</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Tabbara</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Arellanes-Garcia</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature</article-title>
          <source>Am J Ophthalmol</source>
          <year>2001</year>
          <volume>131</volume>
          <fpage>647</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="pmid">11336942</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinot-Peignoux</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boyer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cazals-Hatem</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Gervais</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Le Breton</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA</article-title>
          <source>Hepatology</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>1000</fpage>
          <lpage>1005</lpage>
          <pub-id pub-id-type="pmid">11679971</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dees</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Forrester</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis</article-title>
          <source>Arch Ophthalmol</source>
          <year>1998</year>
          <volume>116</volume>
          <fpage>1456</fpage>
          <lpage>1461</lpage>
          <pub-id pub-id-type="pmid">9823346</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ta&#xEF;eb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Picardo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical practice. Vitiligo</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>160</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="pmid">19129529</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>The patient's face before treatment (A). The 5-cm vitiligo on the forehead appears after 9 months of pegylated interferon-&#x3B1;2b and ribavirin combination therapy (B).</p>
      </caption>
      <graphic xlink:href="kjhep-17-61-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Retinal fluorescein angiography reveals characteristic multiple pinpoint leakages of fluorescein from the choroid into the subretinal space on the right eye (A) and the left eye (B).</p>
      </caption>
      <graphic xlink:href="kjhep-17-61-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Optimal coherence tomography of the right eye shows serous retinal detachments (arrows) with subretinal septa (A). The retinal detachment improved at 2 weeks after the steroid therapy (B).</p>
      </caption>
      <graphic xlink:href="kjhep-17-61-g003"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Revised criteria for diagnosis of Vogt-Koyanagi-Harada disease<sup>*</sup></p>
      </caption>
      <graphic xlink:href="kjhep-17-61-i001"/>
      <table-wrap-foot>
        <fn>
          <p><sup>*</sup>Adapted from Read et al.<xref ref-type="bibr" rid="B17">17</xref></p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
